1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: Insulin

Competitor Analysis: Insulin

  • April 2013
  • -
  • La Merie Publishing
  • -
  • 89 pages

Product description

The Competitive Intelligence Report Insulin as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant insulin and insulin analogs for the treatment of type 1 and type 2 diabetes mellitus. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Total sales of branded recombinant human insulin and insulin analog products in regulated markets were US$ 18.8 bln. This huge market potential has to be defended by the major players and attracts interest from newcomers, technology developers and biosimilar companies. New developments are focused on ultra-fast and ultra-long acting insulins and convenient combinations. A strongly emerging class are oral presentation forms of insulin in clinical development.

The report provides information on the marketed insulin preparations and includes a compilation of current active projects in research and development of novel insulin products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of insulin products and projects. Competitor projects are listed in a tabular format providing information on:
• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Insulin
Table of Contents

2012 Sales of branded recombinant human insulins in regulated markets
2012 Sales of branded short-acting recombinant human insulin analogs in regulated markets
2012 Sales of branded long-acting recombinant human insulin analogs in regulated markets
Rhu insulin (2nd generation) in regulated markets
Biosimilar rhu insulin (2nd generation) in regulated markets
Rhu insulin analogs (3rd generation) in regulated markets
Biosimilar rhu insulin analogs (3rd generation) in regulated markets
Ultra-long acting rhu insulin formulations and insulin analogs (4th generation)
Ultra-fast acting rhu insulin formulations and insulin analogs (4th generation)
Combinations of modern basal and prandial insulin and analogs (4th generation)
Combinations of insulin and GLP-1 agonist (4th generation)
Other combinations with insulin
Oral and Transbuccal Insulins (5th generation)
Inhaled and transdermal insulin
Novel approaches for insulin therapy
Rhu insulin (2nd generation) in non-regulated markets: India
Rhu insulin (2nd generation) in non-regulated markets: China
Rhu insulin (2nd generation) in non-regulated markets: Other Territories
Modern insulin analogs (3rd generation) in non-regulated markets
Animal insulins (1st generation)
Corporate Insulin Product Portfolios and RandD Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects Summary Type 2 diabetes ...

US Market Report for Insulin 2017 - MedCore

US Market Report for Insulin 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The U.S. insulin market can be segmented by insulin type, yielding four segments: long-acting insulin, rapid-acting insulin, premixed insulin and human insulin. In 2016, the largest segment ...

United Kingdom Insulin Delivery Market Outlook to 2022

United Kingdom Insulin Delivery Market Outlook to 2022

  • $ 4995
  • Industry report
  • January 2017
  • by Global Data

United Kingdom Insulin Delivery Market Outlook to 2022 Summary GlobalData’s new report, "United Kingdom Insulin Delivery Market Outlook to 2022", provides key market data on the United Kingdom Insulin ...


Download Unlimited Documents from Trusted Public Sources

Insulin Market and Diabetes Statistics in the US

  • January 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

  • January 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Influenza Statistics in India

  • January 2017
    6 pages
  • Influenza  

    Vaccine  

    Diabetes  

  • India  

    United States  

View report >

Related Market Segments :

Insulin

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.